CDX-1140

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameCDX-1140
Drug Alias NameCDX-1140
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerOropharyngeal Squamous Cell Carcinoma (OPSCC) +[39] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelldex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesCelldex TherapeuticsNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsUveal melanomaMetastatic breast cancerOropharyngeal Squamous Cell Carcinoma (OPSCC) +[36] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A